AB Science S.A. ABSCF
Set alert
1.12 USD 0.00 0.00%
At close · Oct 30
2.70 Day range 2.70
1.12 52-week range 2.70
- YTD
- -22.76%
- 1 year
- -11.11%
- Open
- 2.70
- Prev close
- 1.12
- Mkt cap
- 108.11M
- Vol
- 1.45K
- Avg vol
- 0
- EPS
- -0.03
- P/E
- 0.00
More statistics
- Low
- 2.70
- High
- 2.70
2Y chart
Signals (17)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | May 21, 2026 | 5 months ago |
| SMA: Bearish | May 4, 2026 | 6 months ago |
| MACD: Sell Signal | May 4, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 28, 2026 | 6 months ago |
| RSI: Oversold | Apr 8, 2026 | 6 months ago |
| MACD: Sell Signal | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Dec 22, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 22, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 16, 2025 | 10 months ago |
| RSI: Overbought | Nov 25, 2025 | 11 months ago |
| MACD: Buy Signal | Jun 27, 2025 | 1 year ago |
| SMA: Bearish | Jun 6, 2025 | 1 year ago |
| RSI: Oversold | Jun 6, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 6, 2025 | 1 year ago |
| SMA: Bullish | Feb 13, 2025 | 1 year ago |
| RSI: Overbought | Feb 13, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 2, 2025 | 1 year ago |
News
- AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS
- AB Science : Stonegate Capital Partners updates its coverage of AB Science's stock with a target price of EUR 4.25 per share
- AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share
- AB Science reports its revenues for the year 2025 and provides an update on its activities
- AB Science announces the successful completion of a EUR 3.2 million private placement
- AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
- AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
- AB Science provides an update on its clinical development program.
- AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS
- Stonegate Capital Partners Initiates Coverage on AB Science S.A. (AB)
Your note
Sign in to keep a note on ABSCF — it syncs with the Stock Master app.